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Abstract. In 2010, toxigenic Vibrio cholerae was newly introduced to Haiti. Because resources are limited, decision-
makers need to understand the effect of different preventive interventions. We built a static model to estimate the
potential number of cholera cases averted through improvements in coverage in water, sanitation and hygiene (WASH)
(i.e., latrines, point-of-use chlorination, and piped water), oral cholera vaccine (OCV), or a combination of both. We
allowed indirect effects and non-linear relationships between effect and population coverage. Because there are limited
incidence data for endemic cholera in Haiti, we estimated the incidence of cholera over 20 years in Haiti by using data
from Malawi. Over the next two decades, scalable WASH interventions could avert 57,949–78,567 cholera cases, OCV
could avert 38,569–77,636 cases, and interventions that combined WASH and OCV could avert 71,586–88,974 cases.
Rate of implementation is the most influential variable, and combined approaches maximized the effect.
INTRODUCTION
In October 2010, cholera was introduced to earthquake-
stricken Haiti.1 Within days of its introduction, a National
Cholera Surveillance System was implemented.1 Through June
30, 2013, Haiti had reported 663,134 cases of cholera (Figure 1)2;
of these, 366,995 (55.3%) were hospitalized and 8160 (1.2%)
died. As we approach the three-year mark, cholera will likely
be considered endemic to Haiti.
Water, sanitation, and hygiene (WASH) interventions,
such as latrines, point-of-use chlorination and piped water,
have long been recognized as effective prevention measures
against cholera and other diarrheal diseases.3–12 In 2008, 63%
of the Haitian population had access to improved water and
17% to improved sanitation.13 In 2010, after the earthquake,
the Haitian Directorate for Potable Water and Sanitation
reported that 26% of the rural population received improved
water and 10% improved sanitation; in the Port-au-Prince
metropolitan area, the coverage was 35% and 20%, respec-
tively (Haitian Directorate for Potable Water and Sanitation
five-year plan). Many public health scientists believe that
sustained improvements in access to safe water and sanitation
can eliminate transmission of cholera in Haiti, citing interven-
tions used throughout South and Central America in the
1990s.14,15 The WASH interventions, including hand washing,
have the additional benefit of reducing the incidence of other
diarrheal and respiratory diseases.3,5,16,17 Although improving
water and sanitation infrastructure is the ultimate goal of the
Haitian Government and the international community, it will
take considerable time.18
Oral cholera vaccine (OCV) has been proposed as an effec-
tive adjunct for cholera control in endemic and epidemic set-
tings.19,20 Two whole-cell, killed, World Health Organization–
prequalified OCVs are available: DukoralÒ (Crucell, Stockholm,
Sweden) and Shanchol™ (Shantha Biotechnics, Hyderabad,
India). Both vaccines require two doses given two weeks
apart, with protective immunity developing approximately
one week after the second dose.21,22 The Haitian government
sanctioned two pilot studies23 to assess the acceptability and
feasibility of Shanchol™ vaccine, one in urban Haiti and one
in rural Haiti.24 Based on these pilot study findings and find-
ings from previous OCV studies, the Pan American Health
Organization has recommended targeted or mass OCV cam-
paigns that use Shanchol™ as an intermediate bridge to reduce
cholera transmission in Haiti while improvements in water
and sanitation infrastructure are implemented.24 We present
results of a model that illustrates the potential impact of
WASH and OCV interventions independently and in combi-
nation. These results can aid public health decision makers in
allocating resources to prevent cholera transmission in Haiti.
METHODS
We used Excel 2010 (Microsoft, Redmond, WA) to develop
a spreadsheet-based, static mathematical model in which we
allowed a degree of indirect protection (or herd immunity) for
OCV and WASH interventions by including non-linear rela-
tionships between percentage of population covered and per-
centage of population effectively protected (i.e., for a given
percentage vaccinated or who received WASH interventions,
an additional percentage was also indirectly protected). For
WASH interventions, we included latrines, point-of-use chlo-
rination, and community piped water (standpipes). We divided
Haiti’s population into urban and rural elements. For both
urban and rural populations, and for each intervention, we
constructed three scenarios that illustrated potential rates-of-
growth of coverage over 20 years. We also constructed sce-
narios in which we allowed a combination of WASH and
OCV in rural and urban areas. In these combined scenarios,
we conservatively assumed that persons who received OCV
would not be covered by WASH interventions and vice versa.
Thus, coverage for either WASH or for OCV interventions
would never exceed 50%.Wemodeled 16 scenarios: sixWASH,
six OCV, and four that combined WASH and OCV interven-
tions. For further details, see Online Supplemental Materials.
Demographics and expected annual incidence. We used
current population figures for Haiti stratified by rural and
urban environments, and estimated population growth rate
to project demographic growth over a 20-year period (Supple-
mental Table 1). Because toxigenic Vibrio cholerae was only
recently introduced in Haiti, and cholera incidence has changed
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from an epidemic to an endemic pattern (Figure 1),2 there are
no data describing the incidence of endemic cholera in Haiti
over a 20-year period. Therefore, we estimated the 20-year
annual incidence of endemic cholera in Haiti by using 1990–
2010 annual incidence data from Malawi as reported to the
World Health Organization.25 We chose Malawi because it
faces similar socioeconomic challenges to those seen in Haiti
(e.g., poor roads, relatively high infant mortality rate, large
population without piped water, rates of literacy < 80%).26
We also performed sensitivity analyses by using annual inci-
dence data for endemic cholera from Mozambique and
India, as well as a set of hypothetical annual incidence data
(Online Supplemental Material).
Intervention effectiveness. For each intervention, we
included non-linear relationships between coverage and effec-
tiveness that take into account indirect protective effects27
(Figure 2). For OCV (Shanchol™), we fitted an exponential
curve to the OCV (DukarolÒ) coverage-effectiveness model-
ing data from Longini and others.28 (Figure 2; Supplemental
Table 2). The randomized control trial data for Shanchol™
administered as a two-dose regimen showed a direct efficacy
of 67% after two years, which is nearly identical to that for
DukarolÒ21 and 66% after three years.29,30 Therefore, we
assumed that our use of the DukarolÒ coverage-effectiveness
curve as a proxy for the Shanchol™ coverage-effectiveness
curve was reasonable. We did not examine partial vaccination
effect (i.e., receiving only one dose). The OCV coverage in
our model implies effective coverage with two doses of
Shanchol™ vaccine, and in addition, assumes that all two dose
recipients will receive one booster dose every three years
thereafter (Supplemental Table 4). For latrines and point-
of-use chlorination, we estimated non-linear curves based on
data from two reviews of interventions3,5 (Figure 2; Supple-
mental Table 2). For piped water, we assumed a non-linear
curve with a protective effect of 90% at 100% coverage
(Figure 2; Supplemental Table 2). Because there are little
data on the synergistic effect of one or more WASH interven-
tions, we used a conservative approach and assumed no addi-
tive effect across the various combinations of possible WASH
interventions.7 Therefore, we used a stepwise introduction of
WASH interventions over time, and the intervention with the
stronger protective effect supplanted the other (i.e., piped
water > chlorinated water > latrines). For further detail, see
the Online Supplemental Material.
Intervention coverage over time. For each urban (U) and
rural (R) population, we modeled three rates of intervention
implementation over 20 years for WASH (WASH/U 1, U 2,
U 3 and WASH/R 1, R 2, R 3) and OCV (OCV/U 1, U 2, U 3
and OCV/R 1, R 2, R 3) interventions (Tables 1 and 2; Sup-
plemental Figures 1, 3, and 4). We assumed that five persons
shared one latrine and 50 persons shared one community
piped water standpipe. Point-of use chlorination was assumed
to occur at a household level. We also assumed that in the first
five years of implementation, WASH resources would pri-
marily be allocated towards point-of-use chlorination and that
piped water would begin in year 6.
Figure 2. Coverage-effectiveness curves for various interven-
tions. Black line indicates oral cholera vaccine; dark gray dotted line
indicates piped water; gray dotted-dashed line indicates point-of-use
chlorination; light gray dashed line indicates latrines.
Figure 1. Total (n = 663,134) cholera cases by week, Haiti, October
20, 2010–June 30, 2013.
Table 1
Water, sanitation, and hygiene (WASH) scenarios with percentage











Latrines 10 10 0
Point-of-use chlorination + L 20 80 25
Piped water + C + L 10 10 75
Total 40 100 100
WASH/
U2
Latrines 10 10 0
Point-of-use chlorination + L 20 60 50
Piped water + C + L 10 10 50
Total 40 80 100
WASH/
U3
Latrines 10 10 0
Point-of-use chlorination + L 20 40 80
Piped water + C + L 10 10 20
Total 40 60 100
WASH/
R1
Latrines 10 30 0
Point-of-use chlorination + L 26 40 30
Piped water + C + L 0 0 70
Total 36 70 100
WASH/
R2
Latrines 10 20 8
Point-of-use chlorination + L 26 30 42
Piped water + C + L 0 0 50
Total 36 50 100
WASH/
R3
Latrines 10 10 10
Point-of-use chlorination + L 26 30 42
Piped water + C + L 0 0 25
Total 36 40 77
*C = point-of-use chlorination; L = latrines.
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In addition, we generated two scenarios that combined
WASH and OCV for each of the urban and rural settings
(Table 3). The four combined scenarios differ in coverage rate
achieved by year 20 for each WASH and OCV intervention.
For example, in the first urban and rural combined scenarios
(Combined/U1, Combined/R1), we assumed that OCV reached
peak coverage of 20% at year 5 and then decreased to 5% by
year 20. For the second urban and rural combined scenarios
(Combined/U2, Combined/R2), we assumed that OCV coverage
peaked at 10% in year 5 and then decreased to 0% by year 20.
Number of cholera cases averted. Using endemic cholera
incidence data from Malawi, we calculated potential cases
averted for each scenario by multiplying the estimated inci-
dence and the protective effect of the intervention(s). Cumu-
lative cases averted were discounted by 3% per year.31
Uncertainty/sensitivity analyses. To assess the robust
nature of our model, we performed uncertainty/sensitivity
analyses in three steps. First, we varied the baseline incidence
rates to see if the change in input would change our results.
We used endemic cholera incidence data from Mozambique
(1990–2010) and India (1961–1981) to model countries with
a higher and a lower mean incidence, respectively. We also
created hypothetical scenarios with stable, growing, and
decreasing cholera incidence to determine whether different
secular trends in annual incidence would change our results.
Second, we varied the coverage-effectiveness curves for latrines,
point-of-use chlorination, and community piped water to
enable uncertainty of the estimates of the protective effective-
ness of these WASH interventions. The ranges for their pro-
tective effectiveness at 100% intervention coverage are latrines
(95% confidence interval = 8–46%), point-of-use chlorination
(95% CI = 32–83%), and piped water 90% (default value), and
100% (complete protection) (Supplemental Figure 2). Third,
we varied the implementation rate of WASH, OCV, or a com-
bination of both interventions to determine how the number of
cumulative cholera cases averted would vary.
OCV uncertainty/sensitivity analyses. We varied OCV cov-
erage at year 20 from 1% to 100%. We assumed that effective
OCV coverage increased linearly for 20 years.
WASH uncertainty/sensitivity analyses. For latrines, we
assumed that in urban Haiti, the percentage of persons with
access to latrines only remained the same for the first five
years and then was gradually replaced by point-of-use chlori-
nation or piped water; in rural Haiti, the latrine coverage
increased at a constant rate from 10% at year 0 to 30% at
year 5 and continues to increase at the same rate thereafter
until it is gradually replaced by point-of-use chlorination or
piped water. Point-of-use chlorination coverage remained at
baseline (20% in urban areas and 26% in rural areas) through
year 20, or increased to various levels by year 5 (30%, 50%,
70%, or 90% in urban and rural areas, respectively), increas-
ing thereafter through year 20 in the absence of piped water.
Piped water coverage remained at baseline (10% in urban
areas and 0% in rural areas) for the first five years, increasing
thereafter through year 20.
Combined WASH and OCV uncertainty/sensitivity analyses.
In our combined scenarios, we assumed that the respective
coverage of OCV and WASH does not exceed 50%. Those
persons who would receive OCV would not receive any
WASH interventions and vice versa. We assumed that latrine
only coverage remained at the baseline (10%) until those
persons also received point-of-use chlorination or piped water
interventions. Point-of-use chlorination coverage increased
from baseline (20% for urban areas and 26% for rural areas)
to 30% at year 5, and continued to increase at a constant rate
until piped water replaced it (sensitivity analysis scenario 1);
or its coverage remained unchanged at the baseline from year
0 to year 5 and remained unchanged for subsequent years
until piped water replaced it (sensitivity analysis scenario 2).
Piped water coverage remained at baseline (10% in urban
areas and 0% in rural areas) for the first 5 years, and increased
at a constant rate thereafter to reach 10%, 20%, 30%, 40%, or
50%, respectively, by year 20. The OCV coverage increased
at a constant rate from 1% (baseline) at year 0, peaked at year
5, and decreased thereafter at a constant rate to reach 5% at
year 20. We varied the OCV coverage attained at year 5 from
1% (baseline) to 50%. Finally, we ran two sets of sensitivity
analyses of the four combined interventions in which we first
assumed that OCV coverage increased at a constant rate from
1% baseline at year 0 and reached 50% at year 5, and then
either decreased at a constant rate to 5% at year 20 or
remained at 50% through year 20 (i.e., no decrease) (see
Online Supplemental Material).
RESULTS
We developed eight urban scenarios (three WASH, three
OCV, and two WASH/OCV combined) and eight rural
Table 2
Oral cholera vaccine (OCV) scenarios with percentage of Haitian
urban (U) and rural (R) population covered at years 0, 5, and 20
Scenarios Year 0 (%) Year 5 (%) Year 20 (%)
OCV/U1 1 50 90
OCV/U2 1 20 60
OCV/U3 1 10 25
OCV/R1 1 50 65
OCV/R2 1 20 40
OCV/R3 1 10 25
Table 3
Combined oral cholera vaccine (OCV) and water, sanitation and
hygiene (WASH) scenarios by percentage of Haitian urban (U)








Combined/U1 OCV 1 20 5
WASH sub-total 40 50 50
Latrines 10 10 0
Point-of-use chlorination + L 20 30 0
Piped water + C + L 10 10 50
Combined/U2 OCV 1 10 0
WASH sub-total 40 50 50
Latrines 10 10 0
Point-of-use chlorination + L 20 30 25
Piped water + C + L 10 10 25
Combined/R1 OCV 1 20 5
WASH sub-total 36 40 50
Latrines 10 10 0
Point-of-use chlorination + L 26 30 0
Piped water + C + L 0 0 50
Combined/R2 OCV 1 10 0
WASH sub-total 36 40 50
Latrines 10 10 0
Point-of-use chlorination + L 26 30 25
Piped water + C + L 0 0 25
*C = point-of-use-chlorination; L = latrines.
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scenarios (three WASH, three OCV, and two WASH/OCV
combined). WASH scenario 1 (WASH/R1 + WASH/U1)
averted 78,567 cases of cholera. WASH scenario 2 (WASH/
R2 + WASH/U2) averted 71,106 cases of cholera. WASH
scenario 3 (WASH/R3 + WASH/U3) averted 57,949 cases of
cholera (Tables 1 and 4, Figure 3).
OCV scenario 1 (OCV/R1 +OCV/U1) averted 77,636 cases
of cholera. OCV scenario 2 (OCV/R2 + OCV/U2) averted
57,668 cases of cholera. OCV scenario 3 (OCV/R3 + OCV/
U3) averted 38,569 cases of cholera (Tables 2 and 4,
Figure 3).
The rate of intervention coverage extension had the largest
effect on cases of cholera averted (the difference between
scenarios 1, 2 and 3 for either WASH or OCV).
Combined scenario 1 (Combined/R1 + Combined/U1)
averted 88,974 cholera cases. Combined scenario 2 (Combined/
R2 + Combined/U2) averted 71,586 cholera cases (Tables 3
and 4, Figure 3).
In our sensitivity analyses, we found that although the abso-
lute number of cases of cholera averted is sensitive to the
expected number of cholera cases given different baseline
annual incidence of cholera, the relative effect of each inter-
vention scenario is the same (Figure 4; Supplemental Figure 1).
Our sensitivity analysis of combined interventions (Figure 5)
demonstrated decreasing returns on investment (marginal
increase of the number of cholera cases averted) when OCV
coverage at year 5 and piped water coverage at year 20 are
high. The OCV coverage of 30% at year 5 achieved similar
outcomes with that of 50% coverage at year 5, regardless of
piped water coverage of 10–50% at year 20 (Online Supple-
mental Material).
In our final sensitivity analysis, we explored scenarios to
assess the impact on cases averted after a more rapid scale
up of OCV coverage by year 5, as well as scenarios with
sustained OCV coverage to year 20 (Table 5). In our four
combined scenarios described in Table 3, OCV coverage
reached either 20% or 10% at year 5, and decreased to 5%
or 0% by year 20, respectively (Combined/U1, Combined/
R1, Combined/U2, Combined/R2). For Combined/U1 + R1,
effective OCV coverage increased from 1% at year 0 at a
constant rate, reached 20% at year 5, then decreased at a
constant rate to 5% at year 20 (Table 3), thereby averting
88,974 cases over 20 years (Table 4). If in this scenario,
effective OCV coverage was allowed to reach 50% at year
5, and then decrease at a constant rate to 5% at year 20, an
additional 6,738 cases (95,712 cases) would be averted
(Table 5). For Combined/U2 + R2, effective OCV coverage
increased from 1% at year 0 at a constant rate, reached 10%
at year 5, then decreased at a constant rate at 0% at year 20
(Table 3), thereby averting 71,586 cases over 20 years
(Table 4). If in this scenario, effective OCV coverage were
allowed to reach 50% at year 5, and then decrease at a con-
stant rate to 5% at year 20, an additional 23,933 (95,519 cases)
would be averted (Table 5). However, we estimated very
small further increases in cases averted when we allowed for
effective OCV coverage to reach 50% by year 5 and remain
Table 4
Comparisons of the cumulative number of cases of cholera averted by oral cholera vaccine (OCV) and water, sanitation and hygiene (WASH)
scenarios applied to Haitian urban (U) and rural (R) populations by using Malawi, Mozambique, and India 20-year endemic cholera incidence
data as baseline*
Baseline incidence rate as applied to Haiti† U/R WASH 1 WASH 2 WASH 3 OCV 1 OCV 2 OCV 3 Combi 1 Combi 2
Malawi (1990–2010) U 42,828 41,072 34,794 38,793 29,704 19,093 46,213 38,913
R 35,739 30,034 23,155 38,843 27,964 19,476 42,761 32,673
Total 78,567 71,106 57,949 77,636 57,668 38,569 88,974 71,586
Mozambique (1990–2010) U 61,879 59,313 49,427 59,223 45,931 29,529 65,384 54,827
R 52,541 43,865 33,452 59,229 43,085 30,121 62,704 47,076
Total 114,420 103,178 82,879 118,452 89,016 59,650 128,088 101,903
India (1961–1981) U 3,711 3,530 3,010 3,421 2,508 1,588 4,124 3,473
R 2,911 2,454 1,956 3,437 2,387 1,620 3,753 2,856
Total 6,622 5,984 4,966 6,858 4,895 3,208 7,877 6,329
*Combi = combination of WASH and OCV.
†Total cumulative cholera incidence (with a discounting rate of 3% per year): Malawi baseline incidence rate scenario: 106,994 cases; Mozambique baseline incidence rate scenario: 142,754 cases;
India baseline incidence rate scenario: 9,635 cases.
Figure 3. Cumulative cases of cholera averted by water, sanita-
tion and hygiene (WASH) interventions, oral cholera vaccine inter-
ventions (OCV) or a combination of both (Combi) over a 20-year
period in Haiti, and assuming a baseline national cholera incidence
rate from Malawi (1990–2010) applied to urban and rural Haiti.
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at that level to year 20 (Table 5). For example, in modi-
fied scenario Combined/U1 + R1, sustaining 50% coverage
from year 5 through year 20 resulted in 95,777 cases averted
(i.e., an additional 65 cases averted). Similar modest increases
in case averted (95,703 cases averted; i.e., an additional 184 cases
averted) were estimated for Combined/U2 + R2 (Table 5).
For results of the other sensitivity/uncertainty analyses, see
Online Supplemental Material.
DISCUSSION
Our results demonstrate that the rate of expanding cover-
age of WASH and OCV interventions affects the cumulative
number of cases of cholera averted. The scenarios demon-
strate that the modeled WASH and OCV interventions
averted similar numbers of cholera cases. The assumptions
of coverage for this model took into consideration the theo-
retical implementation of WASH and OCV interventions.
Our goal was to demonstrate the scope of results given
different rates of implementation and levels of coverage
attained through a variety of scenarios, as well as with the
sensitivity and uncertainty analyses. Scenarios that combined
WASH and OCV interventions were most effective, which
supports current efforts to implement both interventions
when feasible.24
The WASH infrastructure provides a long-term, sustain-
able solution for prevention of cholera.12 Evidence from
Europe and North America over the past two centuries, and
more recently from Latin America, demonstrate that as water
and sanitation coverage improves, the risk of epidemic or
endemic cholera transmission is greatly reduced.12,14,15 WASH
also prevents the transmission of many other diarrheal dis-
eases, which in Haiti, as in many developing countries, is a
leading killer of children less than five years of age.32,33 The
overall benefit of expanding WASH coverage extends far
beyond its effect on cholera alone.
The OCVs should help reduce the burden of cholera while
WASH coverage is expanded, given the considerable amount
of time required to improve WASH infrastructure (e.g., piped
water and sewers). However, an OCV program should not be
Figure 5. Cumulative cholera cases averted over 20 years in Haiti
by combined water, sanitation and hygiene (WASH) and oral cholera
vaccine (OCV) intervention scenarios. The x-axis refers to OCV cov-
erage at year 5, and the different lines refer to the proportion of total
piped water coverage (10%, 20%, 30%, 40%, and 50%) at year 20.
We assumed that 1) persons who received OCV would not be covered
by WASH interventions and vice versa; 2) WASH and OCV interven-
tions never exceed 50%, respectively; 3) point-of-use chlorination
increases from 20% (urban), or 26% (rural) and will remain the same
until piped water takes over (provided assumption 1 met); 4) latrine
coverage remains 10% until it is taken over by point-of-use chlorina-
tion or piped water; 5) piped water baseline = 0% in rural areas and
10% in urban areas, and piped water coverage starts increasing at a
constant rate from year 6 onwards; and 6) OCV coverage increases
at a constant rate from 1% baseline at year 0, peaks at year 5 and
decreases thereafter at a constant rate to reach 5% at year 20.
Figure 4. Cumulative cases of urban (U) cholera cases averted by water, sanitation and hygiene (WASH/U1), oral cholera vaccine (OCV/U1)
and a combination of WASH and OCV (Combined/U 1) scenarios when 20-year baseline annual incidence data from Malawi (1990–2010),
Mozambique (1990–2010) and India (1961–1981) are applied to Haiti demographic data.
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considered as a long-term alternative substitute for WASH.
Implementation of OCVs will present its own challenges.
Currently available OCVs are not 100% efficacious, induced
immunity wanes over time thereby requiring periodic booster
dosing, and today’s globally available OCV supply is not suf-
ficient to vaccinate the entire Haitian population with the
required two-dose regimen. In addition, evidence from the
routine childhood expanded program for immunizations
and recent nationwide vaccine campaigns in Haiti has
demonstrated varying ranges of coverage.34–37 Although rapid
expansion of effective OCV coverage to 50% of Haitian
population (10 million doses of administered vaccine or more)
by year 5 may avert an additional 6,000–24,000 cases (Table 5),
such rapid expansion is likely beyond the country’s current
capacity. Therefore, we highlight coverage scenarios (Table 3)
in our model that we believe could be realistically achieved
based on Haiti’s recent experience with routine expanded
program for immunizations and vaccine campaigns.
Our study has several limitations. First, we chose a static
model while simultaneously incorporating an indirect effect
by applying non-linear coverage-effective curves to WASH
and OCV interventions. Thus, the model takes into account
the current effect of an intervention (direct and indirect
protection) and is an improvement over a classical static
model. Unlike a model that simulates the transmission
dynamics of cholera over time (e.g., ordinary differential equa-
tion models),38 a static model does not account for the future
effect of the current intervention because the baseline inci-
dence does not take into account the intervention applied
in the previous year(s). However, our static model, like
others,39,40 avoids having to estimate uncertain and unknown
parameters required for dynamic models that explore the
impact of multiple interventions introduced at various stages
over time.41 More data will be needed to reduce the parameter
uncertainty of existing dynamic models of cholera for Haiti.41,42
Second, although we accounted for population growth, we
did not account for the likely migration of the Haitian popu-
lation from rural to urban areas over the next 20 years.
Third, we recognize that the baseline 20-year annual cholera
incidence data from Malawi, Mozambique, and India that
we used as illustrations for medium, high, and low incidence,
respectively, may have been subject to under-reporting. How-
ever, our findings were robust across all three baseline country
scenarios. However, it is clear that every country’s experience
with endemic cholera is unique. Only time will tell what
Haiti’s experience will be. Fourth, apart from modeling
urban and rural Haiti separately, we did not study the impact
of geographic variation on cholera incidence and interven-
tion implementation (e.g., targeted immunization). Fifth, we
acknowledge the uncertainty associated with the coverage-
effectiveness curve used for each intervention. However,
because data are sparse for OCV and WASH intervention
coverage-effectiveness curves, we used modeling outputs
of Longini and others28 to fit our exponential curves for
OCV, and we also applied exponential curves to the WASH
coverage-effectiveness relationship.27
Our study emphasizes that intervention coverage affects
variation in estimated number of cumulative cholera cases
averted over an extended period, and demonstrates the prob-
able synergistic effects of WASH and OCV when used in
combination. Our study should not be interpreted as an exact
prediction for the number of cholera cases that could be
averted in Haiti under the scenarios outlined, but it serves to
demonstrate that WASH and OCV interventions can play an
important role in decreasing the burden of cholera, and that
maximizing intervention coverage is the central variable to
their success. Transmission and intervention dynamics need
to be understood so that informed decisions can be made
about how to allocate limited resources. The Haitian Govern-
ment recently released its National Plan for the Elimination
of Cholera.18 This plan outlines a combination of public
health interventions that include the use of OCV while expand-
ing access to clean water and sanitation. Our study suggests
that this combined strategy will be effective.
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Table 5
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